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Background: Drug-eluting stents with biodegradable polymers have been developed
to address the risk of very late adverse events such as stent thrombosis. The purpose of
this analysis was to compare safety and efﬁcacy of the biodegradable polymer-coated
biolimus-eluting stent (Nobori, Terumo, Tokyo, Japan; BES) to the durable poly-
mer-coated everolimus-eluting stent (Xience V or Prime, Abbott Vascular, Santa
Clara, CA, USA, or Promus, Boston Scientiﬁc, Natick, MA, USA; EES) in an all-
comer population at 3-year follow-up.
Methods: The COMPARE II study was an open-label, prospective, randomized, non-
inferiority, all-comers trial undertaken at 12 sites across Europe. Patients were
randomly allocated (2:1) to receive either a BES or EES. The primary endpoint was a
composite of safety (cardiac death or non-fatal myocardial infarction; MI) and efﬁcacy
(clinically indicated target vessel revascularization; CI-TVR), analyzed by intention to
treat.
Results: Of the 2707 study patients (4025 lesions), 2683 (99.1 %) completed 3
years follow-up. At 3 years the BES was equivalent to the EES with the primary
endpoint (cardiac death, MI, or CI-TVR) occurring in 196 patients (10.9 %) in the
BES group and 96 patients (10.5 %) in the EES group (relative risk 1.04 [95% CI
0.82-1.31], p-value 0.76). The individual endpoints for MI, CI-TVR and deﬁnite or
probable stent thrombosis between BES and EES were similar (5.2% vs. 4.6%,
p¼0.52 for MI; 6.4 % vs. 5.8%, p¼0.58 for CI-TVR; 1.3% vs. 1.4%, p¼0.76 for
def./prob. stent thrombosis). Interestingly, subgroup analysis revealed a signiﬁcant
interaction between stent type and presence of diabetes on the primary endpoint
suggesting EES being superior in diabetic subjects (18% vs. 11%, p¼0.04; p-value
for interaction 0.04).
Conclusions: At 3-year follow-up the biodegradable polymer-coated BES is equiv-
alent regarding clinical outcomes to the durable polymer-coated EES, yet does not
indicate any beneﬁts towards reduction of very late adverse events. Moreover, EES
might be superior to BES in diabetic patients.TCT-585
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Background: No randomized data regarding optical coherence tomography (OCT)
evaluation at post-procedure and 3 months follow-up exists following platinum-
chromium everolimus-eluting stent (PtCr-EES) vs. cobalt-chromium everolimus-
eluting stent (CoCr-EES).
Methods: A total of 100 patients were randomly assigned into PtCr-EES (n¼49) and
CoCr-EES (n¼51) and then OCT was serially evaluated after stent deployment with
nominal pressure and ﬁnal post-procedure, and 3-month. The primary endpoint was
the incidence of acute stent malapposition after nominal pressure and ﬁnal post-
procedure.
Results: Compared to CoCr-EES, PtCr-EES showed a signiﬁcantly lower
incidence of stent malapposition at nominal pressure (96% vs. 78%, p¼0.015)
but no signiﬁcant difference at post-procedure (78% vs 69%, p¼0.315).
Percent cross-section with any malapposed struts was signiﬁcantly lower inB170 JACC Vol 64/11/Suppl B j SeptemberPtCr-EES at nominal pressure (median; 15.0% vs. 23.8%, p¼0.036) and ﬁnal
post-procedure (6.5% vs. 10.5%, p¼0.026). On 3-month follow-up, both PtCr-
and CoCr-EES showed comparable % malapposed (0% vs. 0%, p¼0.332)
or uncovered struts (5.3% vs. 4.7%, p¼0.829). There were signiﬁcant
correlation between % malapposed struts at post-procedure and % uncovered
(r¼0.430, p< 0.001) or malapposed struts (r¼0.537, p< 0.001) at 3 months
(See ﬁgure).Conclusions: This randomized trial showed that, compared to CoCr-EES, PtCr-
EES has a better post-procedural strut apposition but no signiﬁcant difference
of strut coverage at 3 month follow-up. The percent malapposed struts at post-
procedure was signiﬁcantly correlated with the strut coverage at 3-month
follow-up.
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Background: Evaluate the long-term safety and effectiveness of the Elixir DESyne
BD Novolimus Eluting Coronary Stent System (NECSS), a Co-Cr stent with a
biodegradable polymer compared to the control Endeavor Zotarolimus Eluting Cor-
onary Stent System (ZECSS) (Medtronic, Santa Rosa, CA).
Methods: 149 patients were randomized 3:1, either to the DESyne BD NECSS or
to the Endeavor ZECSS. Patients were analyzed for the primary endpoint of in-
stent late lumen loss (LLL) assessed by qualitative coronary angiography (QCA)
at 6 months. Secondary endpoints were evaluated at 1, 6, 9, and 12 months
and annually through 5 years, and included device-orientated composite endpoint
(DoCE) deﬁned as: cardiac death, target vessel MI, clinically-indicated target
lesion revascularization (TLR); clinically-indicated target vessel revascularization
(TVR); and stent thrombosis. Lesions were also evaluated for 6-month angio-
graphic endpoints including: in-segment LLL, percent diameter stenosis, post-
procedure minimal lumen diameter, and angiographic binary restenosis (ABR)
(50%). A subset of patients underwent 6-month intravascular ultrasound (IVUS)
evaluation.
Results: The study met the primary endpoint demonstrating both non-inferiority
and superiority of the DESyne BD compared to the control (0.120.15 vs
0.670.47, p< 0.001). Six-month in-stent ABR was signiﬁcantly lower for
DESyne BD (0% vs 7.9%, p¼0.003). Excellent clinical results were demon-
strated for both devices with sustained low clinical event rates observed through
24 months (Table 1). Long-term clinical results through 36 months will be
presented.13–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Randomized Trials
